Genflow Biosciences (GENF) Share Price, News & Analysis

Company Overview

Genflow Biosciences plc is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.

Key Stats

• Today's Range: 1.82 to 2
• 50-Day Range: 1.45 to 2.17
• 52-Week Range: 1.32 to 3.41
• Volume: 1.29 million shs
• Average Volume: 1.31 million shs
• Market Capitalization: £6.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GENF Stock Analysis - Frequently Asked Questions

How have GENF shares performed this year?

Genflow Biosciences' stock was trading at GBX 1.80 at the beginning of 2025. Since then, GENF shares have increased by 11.1% and is now trading at GBX 2.
View the best growth stocks for 2025 here.

How do I buy shares of Genflow Biosciences?

Shares of GENF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Genflow Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genflow Biosciences investors own include Aehr Test Systems (AEHR), Advanced Micro Devices (AMD), ARM (ARM), Medical Properties Trust (MPW), NIO (NIO), NVIDIA (NVDA) and PayPal (PYPL).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:GENF
• CUSIP: N/A
• CIK: N/A
• Web: genflowbio.com
• Phone: 44 32 4774 95881
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-1,760,791.46
• Net Margins: 778.46%
• Pretax Margin: N/A
• Return on Equity: -208.12%
• Return on Assets: -58.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.09
• Quick Ratio: 20.20

Sales & Book Value

• Annual Sales: £-226,187.99
• Price / Sales: -30.14
• Cash Flow: GBX 0.67 per share
• Price / Cash Flow: 3.00
• Book Value: GBX 0.25 per share
• Price / Book: 8.06

Miscellaneous

• Outstanding Shares: 340,919,077
• Free Float: N/A
• Market Cap: £6.82 million
• Optionable: Not Optionable
• Beta: 2.37